Harnessing the power of ionising radiation to enhance cancer immunotherapy

References

[1] Lim YJ, Koh J, Kim S, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys. 2017; 99: 1216-1224.

[2] Yang Y, Wu M, Cao D, et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv. 2021; 7: eabf6290.

[3] Yang Y, Pang K, Lin G, et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nat Med. 2025; 31: 449-456.

[4] Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021; 22: 824-835.

[5] Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022; 40: 1301-1311.

[6] Galluzzi L, Aryankalayil MJ, Coleman CN, et al. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023; 20: 543-557.

[7] Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020; 26: 566-576.

[8] Subbiah V, Gouda MA, Ryll B, et al. The evolving landscape of tissue-agnostic therapies in precision oncology. CA Cancer J Clin. 2024; 74: 433-452.

[9] Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; 386: 2363-2376.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.